Election 2024How We SurviveOffice PoliticsI've Always Wondered ...My Economy

Loading...

0:00
0% played
Support the fact-based journalism you rely on with a donation to Marketplace today. Give Now!
Stories Tagged as

Medicare Part B

Medicare rejected a controversial Alzheimer's drug. Participants still ended up paying for it.

by Lily Jamali
Oct 24, 2022
Medicare raised premiums late last year in preparation to cover the drug Aduhelm. Ultimately, Medicare rejected coverage of the drug, with limited exceptions.
Biogen initially priced its Alzheimer’s treatment drug at $56,000 a year. That figure was factored in when Medicare set Part B premiums late last year.
Dominick Reuter/AFP via Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE